Disease: Gastric Cancer
Trial Design: Phase 2
We partnered NeuVax with Dr. Reddy’s Laboratories Ltd, an international pharmaceutical company based in India, for the commercialization of NeuVax in that region. We currently have an agreement with Dr. Reddy’s Laboratories to conduct a Phase 2 investigational study in gastric cancer in India.
About the Disease
According to the NCI, gastric (stomach) cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Infection with bacteria called Helicobacter pylori (H. pylori) is thought to be the cause of gastric cancer and age, diet, and stomach disease can affect the risk of developing gastric cancer. Gastric cancer is often diagnosed at an advanced stage because there are no early signs or symptoms, and is the second-most common cancer among males and third-most common among females in Asia and worldwide with over 63,000 new cases a year in India, where an initial clinical trial of NeuVax is planned. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas. Overall, without regard to the stage of cancer, only approximately 28% of patients with stomach cancer live at least 5 years following diagnosis.